Table 1

Baseline characteristics of the included patients

ParameterNon-radiographic axial spondyloarthritis (n=95)AS (n=115)All patients (n=210)
Age (years)38.7±9.936.8±11.037.1±10.6
Duration of symptoms (years)3.2±2.25.2±2.84.2±2.7
Male gender (%)33.765.251.0
HLA-B27 (+) (%)72.684.379.0
Peripheral arthritis (%)16.813.014.8
Enthesitis* (%)
Uveitis ever (%)15.823.520.0
Psoriasis ever (%)11.614.813.3
IBD ever (%)
Family history of AS (%)16.816.516.7
BASDAI (points NRS)4.2±2.03.8±2.23.9±2.2
BASFI (points NRS)2.8±2.23.0±2.42.9±2.3
Treatment with NSAID (%)67.466.166.7
Treatment with DMARD (%)27.430.429.0
Treatment with systemic steroids (%)
Treatment with a TNFα blocker (%)
  • * Berlin score with 12 enthesitis points of the lower limbs assessed.12

  • AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; DMARD, disease-modifying antirheumatic drug; HLA-B27, human leucocyte antigen B27; IBD, inflammatory bowel disease; NRS, numeric rating scale; NSAID, non-steroidal anti-inflammatory drug; TNFα, tumour necrosis factor alpha.